Neurophets AI has obtained FDA 510(k) clearance for their product ‘Neurophet AQUA’.

WNPH | Neurophet AI, a company specializing in solutions for brain diseases, announced on November 25, 2024, that its brain MRI analysis software “Neurophet AQUA” has received FDA 510(k) clearance for advanced analysis of multiple sclerosis (MS) and white matter hyperintensities. This clearance expands the software’s capabilities beyond brain atrophy analysis to target neurodegenerative conditions.

The initial clearance, obtained in May of the previous year, allowed for brain atrophy analysis using T1-weighted images from MRI scans. The newly integrated features now enable precise measurement of MS lesions and structural changes using T2-FLAIR images.

MS is a neurological disorder that primarily affects individuals aged 20 to 40, impacting the central nervous system. Neurophet AQUA’s advanced MS analysis technology enhances efficiency for healthcare professionals, aiding in both diagnosis and prognosis stages.

Given the prevalence of MS in North America and Europe, Neurophet aims to use this FDA clearance to expand its global presence. Established in 2016, Neurophet is dedicated to developing AI solutions for brain diseases, with products like “Neurophet SCALE PET” and “Neurophet tES/TMS LAB” in addition to “Neurophet AQUA”.

Neurophet’s mission is to utilize AI technology to pioneer solutions for brain diseases and improve the health of patiNeurophet AI, a pioneering company specializing in innovative solutions for brain diseases, made a significant announcement on November 25, 2024. The company revealed that its cutting-edge brain MRI analysis software, known as “Neurophet AQUA,” has received the prestigious FDA 510(k) clearance for advanced analysis of multiple sclerosis (MS) and white matter hyperintensities. This milestone marks a significant expansion of the software’s capabilities, shifting its focus from solely analyzing brain atrophy to targeting various neurodegenerative conditions. The initial FDA clearance for “Neurophet AQUA” was secured in May of the previous year. At that time, the software was recognized for its ability to perform brain atrophy analysis using T1-weighted images from MRI scans. With the introduction of new features, the software can now provide precise measurements of MS lesions and structural changes by utilizing T2-FLAIR images. Multiple sclerosis (MS) is a debilitating neurological disorder that primarily affects individuals between the ages of 20 and 40, causing significant impact on the central nervous system. With the advanced MS analysis technology offered by Neurophet AQUA, healthcare professionals now have a powerful tool that enhances efficiency in both the diagnosis and prognosis stages of the disease. Recognizing the prevalence of MS in regions like North America and Europe, Neurophet is committed to leveraging this FDA clearance to expand its global reach and impact. Since its establishment in 2016, Neurophet has been dedicated to developing innovative AI solutions for various brain diseases. In addition to “Neurophet AQUA,” the company also offers products like “Neurophet SCALE PET” and “Neurophet tES/TMS LAB.” The overarching mission of Neurophet is to harness the power of AI technology to pioneer groundbreaking solutions for brain diseases, ultimately striving to improve the health and well-being of patients suffering from neurological disorders. With this latest FDA clearance and the continued advancement of its products, Neurophet is poised to make a lasting impact in the field of neurology and beyond.ents suffering from neurological disorders.